On August 31, 2022 Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, reported that Laurence Reid, Ph.D., Chief Executive Officer, will be participating in the following upcoming investor conferences in September (Press release, Decibel Therapeutics, AUG 31, 2022, View Source [SID1234618805]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi 17th Annual BioPharma Conference:

Rare disease panel on Wednesday, September 7, 2022 at 11:20 a.m. ET in Boston, MA.
H.C. Wainwright 24th Annual Global Investment Conference:

Virtual presentation available for on demand viewing starting on Monday, September 12, 2022 at 7:00 a.m. ET
Baird 2022 Global Healthcare Conference:

Fireside chat on Tuesday, September 13, 2022 at 3:10 p.m. ET in New York, NY.
Cantor Cell & Genetic Medicines Conference:

Panel titled, "Ring Ring: Is That Large-Cap Pharma Calling? Importance of Established Partnerships in Place," on Thursday, September 15, 2022 at 8:00 a.m. ET in New York, NY.
Webcasts of the Citi, H.C. Wainwright and Baird events may be accessed by visiting the Investors section of the Decibel Therapeutics website at View Source An archived replay of the webcasts will be available on the Company’s website for approximately 90 days following these events.